Blood cancers

Clear role for kinase inhibitors in CLL, says expert

Patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) who have to discontinue use of a kinase inhibitor can be salvaged by switching to an alternate drug in the same class. According to a retrospective US study of 178 CLL patients who discontinued either ibrutinib or idelalisib, the sequence of kinase inhibitors for those who switched did ...

Already a member?

Login to keep reading.

© 2021 the limbic